Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
Rhea-AI Summary
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its second quarter financial results announcement for Wednesday, December 11, 2024, after market close. The company will host a conference call at 4:30 P.M. EST to discuss the results for the quarter ended October 31, 2024. Investors can join via phone or access the replay through the company's website within 72 hours.
Positive
- None.
Negative
- None.
News Market Reaction – CSBR
In the trading session that priced this news, CSBR gained 6.22%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31, 2024, on Wednesday, December 11, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 710610. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 51750, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
SOURCE: Champions Oncology, Inc.
View the original press release on accesswire.com